Spectral AI Names Vincent S. Capone as Chief Executive Officer
MWN-AI** Summary
Spectral AI, Inc. has announced the appointment of Vincent S. Capone as Chief Executive Officer, effective February 9, 2026. Previously the company's Chief Financial Officer and General Counsel, Capone steps into this pivotal role as Spectral AI advances towards the commercialization of its non-invasive AI-driven burn wound assessment device, the DeepView® System.
Dr. J. Michael DiMaio, Chairman of the Board, praised Capone’s unique blend of skills in law, accounting, finance, and operations management, highlighting his passion for transforming burn wound assessment and his integral role in the company’s development. Capone has been part of the Office of the Chairman since October 2024, playing a vital role in the company’s operational and strategic decision-making processes.
With a professional background that includes a tenure at KPMG LLP and a partnership at Reed Smith LLP specializing in corporate and securities law, Capone has significant experience in finance and law. He also served as President of a private equity fund prior to joining Spectral AI.
In his new role, Capone expressed excitement about leading the company as it evolves towards commercialization, emphasizing the milestone achievement of submitting the DeepView System to the FDA in June 2025. He aims to deliver this innovative technology to healthcare markets and improve outcomes for burn care patients worldwide.
Spectral AI, based in Dallas, is a predictive AI company dedicated to enhancing medical diagnostics for wound care, particularly for burns. The DeepView System promises to revolutionize clinical assessments, offering objective insights into healing potential, thereby aiming to set a new standard in patient care and healthcare cost reduction.
MWN-AI** Analysis
Spectral AI Inc., now led by the newly appointed CEO Vincent S. Capone, presents an intriguing investment opportunity as it steers toward the commercialization of its DeepView® System. With its focus on AI-driven burn wound assessment, Spectral AI is poised to address a significant challenge in the healthcare sector—offering accurate diagnostics that can enhance patient care while potentially lowering costs.
Capone's deep background in law, finance, and operations is advantageous for the company as it transitions from development to commercialization—a crucial phase that typically incites volatility in share prices. Given Capone's previous roles, including General Counsel and Chief Financial Officer, investors can anticipate a steady hand guiding the company through the complexities of the competitive health tech landscape.
The DeepView System's FDA submission in June 2025 marks a pivotal turning point. Successful approval could drive substantial interest from healthcare providers and investors alike. Spectral AI’s ability to revolutionize wound care by providing clinicians with rapid, algorithm-driven assessments places it in a favorable position within the burgeoning health technology market. Additionally, being recognized in TIME's list of World’s Top HealthTech companies solidifies its credibility and public perception as an innovative leader.
However, investors should remain cognizant of the inherent risks associated with forward-looking statements. Market fluctuations, regulatory hurdles, and competition can adversely affect performance. As the company ramps up towards a full commercial launch, maintaining vigilance regarding market reactions and evaluating the company’s quarterly progress reports will be critical. Overall, Spectral AI holds considerable promise, and investors may find a compelling opportunity here, especially as the healthcare industry increasingly adopts AI solutions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
DALLAS, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the Company’s Board of Directors has appointed Vincent S. Capone as Chief Executive Officer of the Company, effective February 9, 2026.
The appointment of Mr. Capone, who currently serves as the Company’s Chief Financial Officer and General Counsel, comes as Spectral AI transitions towards commercialization of its proprietary, non-invasive, AI-driven burn wound assessment device – the DeepView® System.
“Vince brings a unique set of leadership skills to his new role, combining a background in law, accounting, finance and operations management supported by a strong vision for the Company’s future,” said Dr. J. Michael DiMaio, Chairman of the Board of Spectral AI. “He has a strong passion for our mission to provide clinicians with a novel technology that re-imagines the current standard of care in burn wound assessment. Vince has played an integral role working with me in leading Spectral AI to this point in our development, and he has earned the respect of our Board, leadership, team members, and partners. His appointment as CEO will help to ensure the evolution of our strategic direction with me as Executive Chairman.”
Mr. Capone has served as Spectral AI’s Chief Financial Officer since February 2024 and as General Counsel since March 2022. He has been a member of the Office of the Chairman since October 2024 which, under the leadership of Dr. DiMaio, has been responsible for day-to-day operational responsibilities and support of the clinical development and commercialization of the DeepView System. Mr. Capone began his career at KPMG LLP before practicing corporate and securities law as a partner with Reed Smith LLP. Prior to joining Spectral AI, he was President of a New York-based private equity fund investing in global life sciences and technology companies.
“I am honored to assume the role of CEO as the Company evolves towards commercialization,” said Mr. Capone. “I am also thankful to work alongside a talented team who drive our success every day. Our FDA submission of the DeepView System in June 2025 marked a major milestone for Spectral AI and a critical step forward to providing this innovative and potentially transformative technology. We are excited to deliver DeepView to the broader healthcare market and advance burn wound care in the U.S. and around the world.”
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is being developed as a predictive diagnostic device to offer clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView System is expected to provide fast and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. Spectral AI has been named to TIME’s list of World’s Top HealthTech companies 2025. For more information about the DeepView System, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the US Securities and Exchange Commission, including the Company’s Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
Investors:
The Equity Group
Devin Sullivan
Managing Director
dsullivan@theequitygroup.com
Conor Rodriguez
Associate
crodriguez@theequitygroup.com
FAQ**
What strategic advantages does Spectral AI Inc. Warrants MDAIW provide to investors considering the potential commercialization of the DeepView System under the leadership of newly appointed CEO Vincent S. Capone?
How might the transition of Vincent S. Capone from CFO to CEO impact the financial strategies outlined for Spectral AI Inc. Warrants MDAIW and its future growth in the AI-driven wound care market?
Can you elaborate on the expected timeline for the commercialization of the DeepView System and how it aligns with the terms of Spectral AI Inc. Warrants MDAIW for investors?
What are the key milestones for Spectral AI that investors should monitor to evaluate the performance of Spectral AI Inc. Warrants MDAIW in relation to the company's progress in burn wound care technologies?
**MWN-AI FAQ is based on asking OpenAI questions about Spectral AI Inc. Warrants (NASDAQ: MDAIW).
NASDAQ: MDAIW
MDAIW Trading
6.13% G/L:
$0.45 Last:
174 Volume:
$0.45 Open:
